WALTHAM, Mass. - Dyne Therapeutics, Inc. (NASDAQ:DYN) has appointed Vikram Karnani to its Board of Directors, the clinical-stage neuromuscular disease company announced Tuesday. The appointment comes ...

WALTHAM, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven ...

Enemy Intel Inflicting enough damage will pressure him. When his HP is reduced, he will fuse with scrap metal to perform powerful attacks. During this time, he will be difficult to pressure. However, ...

The biotech announced a secondary stock issue. It aims to sell $300 million worth of common shares. 10 stocks we like better than Dyne Therapeutics › It isn't unusual for a biotech to raise capital ...

The biotech announced a secondary stock issue. It aims to sell $300 million worth of common shares. Just after market close on Monday, Dyne announced that it has launched an underwritten public ...

Nine years after Sarepta Therapeutics’ Exondys 51 won a controversial FDA approval to treat a subset of patients with Duchenne muscular dystrophy (DMD), a challenger from Massachusetts biotech Dyne ...

It was mentioned positively in a new analyst note on the biotech sector. The researchers feel a recent rally in such titles somewhat unfairly left it behind. That research note was published on Sunday ...

A peer is being acquired for a very high premium. The market is clearly thinking Dyne might be next on a potential buyer's shopping list. Both Dyne and Avidity are clinical-stage companies busy ...

Dyne Therapeutics shares were higher Monday after Avidity Biosciences, a competitor developing drugs for neuromuscular disorders, agreed to be sold to Novartis for $12 billion. Dyne shares rose 41% to ...

A peer is being acquired for a very high premium. The market is clearly thinking Dyne might be next on a potential buyer's shopping list. 10 stocks we like better than Dyne Therapeutics › Dyne ...